首页> 外文期刊>FEBS Letters >Antisense inhibition of Bcr‐Abl/c‐Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells1
【24h】

Antisense inhibition of Bcr‐Abl/c‐Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells1

机译:对Bcr-Abl / c-Abl合成的反义抑制可促进端粒酶活性并上调人类白血病细胞中的tanylase。

获取原文
           

摘要

>Clinical studies in chronic myelogenous leukemia demonstrate that the overexpression of Bcr-Abl tyrosine kinase is usually accompanied by relatively low telomerase activity in the chronic phase, which reverts to a high activity in blast crisis. The present study was designed to investigate the cross-talk between both enzymes, using Bcr-Abl-positive K-562 and Bcr-Abl-negative Jurkat cell lines, treated with antisense oligodeoxyribonucleotides (ODNs) against Bcr-Abl/c-Abl mRNA. The decreased amount and enzyme activity of Bcr-Abl/c-Abl provoked telomerase activation in both cell lines. After short-term treatment with anti-Bcr-Abl/c-Abl ODNs (6 days), no variations in hTERT and phospho-hTERT were detected. The decreased amount of Bcr-Abl/c-Abl was accompanied by: alterations in telomeric associated proteins–overexpression of tankyrase and decreased amount of TRF1/Tin2, cell growth arrest of K-562 cells, reaching a plateau after 6 days treatment, and increased proliferating activity of Jurkat cells. No changes in telomere length were detected after short-term treatment. In contrast, after long-term treatment with anti-Bcr-Abl/c-Abl ODNs (36 days), a significant elongation of telomeres and enhancement of hTERT were established, accompanied by an increased proliferating activity of both cell lines. These data provide evidence that the inhibition of Bcr-Abl or c-Abl synthesis keeps a potential to restore or induce cell proliferation through telomere lengthening control and telomerase activation.
机译:>关于慢性粒细胞性白血病的临床研究表明,Bcr-Abl酪氨酸激酶的过度表达通常在慢性期伴随着相对较低的端粒酶活性,在爆炸性危机中恢复为高活性。本研究旨在使用Bcr-Abl阳性K-562和Bcr-Abl阴性Jurkat细胞系研究两种酶之间的串扰,并用针对Bcr-Abl / c-Abl mRNA的反义寡脱氧核糖核苷酸(ODN)处理。 Bcr-Abl / c-Abl的减少量和酶活性引起了两种细胞系中端粒酶的激活。用抗Bcr-Abl / c-Abl ODN短期治疗(6天)后,未检测到hTERT和磷酸化hTERT的变化。 Bcr-Abl / c-Abl的减少伴随有:端粒相关蛋白的改变–端锚聚合酶的过表达和TRF1 / Tin2的减少,K-562细胞的细胞生长停滞,在治疗6天后达到平稳,以及增加Jurkat细胞的增殖活性。短期治疗后未发现端粒长度变化。相反,在用抗Bcr-Abl / c-Abl ODN长期治疗后(36天),建立了端粒的显着延长和hTERT的增强,并伴随着两​​种细胞系增殖活性的提高。这些数据提供了对Bcr-Abl或c-Abl合成的抑制作用,通过端粒延长控制和端粒酶激活,保留了恢复或诱导细胞增殖的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号